University of Kentucky

UKnowledge
Psychiatry Faculty Publications

Psychiatry

12-2-2020

Clinically Relevant Interactions between Atypical Antipsychotics
and Anti-Infective Agents
Edoardo Spina
University of Messina, Italy

Maria Antonietta Barbieri
University of Messina, Italy

Giuseppe Cicala
University of Messina, Italy

Jose de Leon
University of Kentucky, jdeleon@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/psychiatry_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Psychiatry Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Spina, Edoardo; Barbieri, Maria Antonietta; Cicala, Giuseppe; and de Leon, Jose, "Clinically Relevant
Interactions between Atypical Antipsychotics and Anti-Infective Agents" (2020). Psychiatry Faculty
Publications. 53.
https://uknowledge.uky.edu/psychiatry_facpub/53

This Review is brought to you for free and open access by the Psychiatry at UKnowledge. It has been accepted for
inclusion in Psychiatry Faculty Publications by an authorized administrator of UKnowledge. For more information,
please contact UKnowledge@lsv.uky.edu.

Clinically Relevant Interactions between Atypical Antipsychotics and AntiInfective Agents
Digital Object Identifier (DOI)
https://doi.org/10.3390/ph13120439

Notes/Citation Information
Published in Pharmaceuticals, v. 13, issue 12, 439.
© 2020 by the authors
This article is an open access article distributed under the terms and conditions of the Creative
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

This review is available at UKnowledge: https://uknowledge.uky.edu/psychiatry_facpub/53

Review
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Abstract: This is a comprehensive review of the literature on drug interactions (DIs) between
atypical antipsychotics and anti-infective agents that focuses on those DIs with the potential to be
clinically relevant and classifies them as pharmacokinetic (PK) or pharmacodynamic (PD) DIs.
PubMed searches were conducted for each of the atypical antipsychotics and most commonly used
anti-infective agents (13 atypical antipsychotics by 61 anti-infective agents/classes leading to 793
individual searches). Additional relevant articles were obtained from citations and from prior
review articles written by the authors. Based on prior DI articles and our current understanding of
PK and PD mechanism, we developed tables with practical recommendations for clinicians for:
antibiotic DIs, antitubercular DIs, antifungal DIs, antiviral DIs, and other anti-infective DIs. Another
table reflects that in clinical practice, DIs between atypical antipsychotics and anti-infective agents
occur in patients also suffering an infection that may also influence the PK and PD mechanisms of
both drugs (the atypical antipsychotic and the anti-infective agent(s)). These tables reflect the
currently available literature and our current knowledge of the field and will need to be updated as
new DI information becomes available.
Keywords: antipsychotic agents; antibacterial agents; antibiotics; antitubercular; antifungal agents;
antimalarials; antiviral agents; drug interactions; pharmacology; pharmacokinetics

1. Introduction
Drug combinations are increasingly used in the treatment of many conditions and represent an
important risk factor for the occurrence of drug interactions (DIs) [1]. A clinically relevant DI occurs
when the efficacy or safety of a drug is altered by the concomitant administration of another
medication. In a few cases, DIs may prove beneficial, resulting in an increased efficacy or reduced
risk of adverse drug reactions (ADRs), and therefore certain drug combinations may be used
advantageously in clinical practice. However, more often, DIs are harmful, leading to diminished
efficacy or increased toxicity of one or more of the administered medications.
Currently available antipsychotic drugs can be divided into typical or first-generation
antipsychotics and atypical or second-generation antipsychotics. In recent years, atypical
antipsychotics (amisulpride, aripiprazole, asenapine, brexipiprazole, cariprazine, clozapine,
iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) have
progressively replaced older, typical agents due to better safety profiles for reversible extrapyramidal
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symptoms and tardive dyskinesia [2]. Moreover, new antipsychotics are increasingly prescribed not
only for schizophrenia and bipolar disorder, but also for other psychiatric conditions such as adjuvant
treatment of major depressive disorder, psychosis and behavioral disorders in dementia, psychosis
associated with Parkinson’s disease, resistant obsessive-compulsive disorder, aggressive behavior,
and irritability in autism spectrum disorders [2]. Over the past few years, a number of reviews have
described the clinically relevant DIs between atypical antipsychotics and various CNS medications
including antiepileptics [3] and antidepressants [4].
Anti-infective agents are medications capable of preventing or treating infections. They include
a number of widely used classes of drugs such as antibiotics, antituberculosis agents, antifungals,
anthelmintics, antimalarials, and antivirals. Many anti-infective medications can lead to DIs [5–7].
Considering the frequent co-prescription of anti-infective agents with atypical antipsychotics, it
is essential for clinicians to be aware of the potential DIs between them. Previous global reviews of
DIs with atypical antipsychotics have also included DIs with anti-infective agents but were not
specifically focused on these combinations [8,9]. The purpose of this article was to provide an
updated review of clinically significant DIs between atypical antipsychotics and anti-infective agents.
2. Methods of Literature Search
After many years of writing articles on antipsychotic DIs [3,4,8], we have figured out that the
challenges of finding articles are completely different compared to systematic searches for metaanalysis in which replication by other authors and elimination of low-quality articles with low level
of evidence is essential. In the area of DIs, there is so little information that it is not easy to find the
articles; therefore, case reports are important, and in their absence, we needed to provide orientation
by extrapolating from other antipsychotics with similar pharmacokinetic characteristics. In some
cases, we found that even DIs from anti-infective agents with other psychiatric drugs or nonpsychiatric drugs were helpful in orienting clinicians when nothing else was available. In summary,
we were not trying to exclude articles but to include any information that may help clinicians. Most
of the articles that we have included in this review came from our article library on DIs accumulated
after writing DI review articles on antipsychotics [3,4,8], which the first and last author keep updating
every day as they find articles in their clinical and/or research activities. To be sure that we were not
missing any articles from prior searchers or any new articles recently published in September of 2020
we tried to use PubMed searches. PubMed has no MeSH heading for DIs, so we needed to complete
many manual searches in a very complex and repetitive way. Each search was done with no time
limit from the beginning of PubMed until the day in September that we completed the search. We
decided to focus only on articles in English. The searches included 13 atypical antipsychotics and 61
anti-infective agents or classes, leading to 793 individual PubMed searches. Considering
erythromycin, for example, we conducted 13 searches by writing in the PubMed search box
“erythromycin AND amisulpride,” “erythromycin AND aripiprazole” and the other 11 atypical
antipsychotics. Additional relevant DI articles were also obtained from citations of the articles that
were retrieved during our search. We also reviewed the Summary of Product Characteristics and
Food & Drug Administration (FDA) prescribing information for each atypical antipsychotic and the
most commonly used anti-infective agents. Similarly, the Micromedex and the Liverpool DI
databases were also searched for any other missing article. In all of these searchers, we only excluded
meeting abstracts because they are not easy to obtain. In summary, our search resulted in 34
combinations between an atypical antipsychotic and an anti-infective agent supported by at least one
DI study and 52 relevant DI articles from peer-review journals were included. The Introduction and
Discussion sections were supported by additional references that helped us to provide a
comprehensive review of the topic. The review of DIs in each class of anti-infective agents was
summarized in a table with a practical summary of how to manage DIs within that class of antiinfective agents based on the authors’ knowledge at the time of publication of this article. Each table
has four columns: anti-infective, atypical antipsychotic, outcome, and actions. When there were
studies or case reports we used them to describe outcomes and we added these references in the
outcome column. Sometimes there is no published article and the outcome is based on extrapolation

Pharmaceuticals 2020, 13, 439

3 of 25

from
other
drugs
with
similar
pharmacological
characteristics
or
pharmacokinetic/pharmacodynamic principles; in this case, no reference is provided. The actions are
ordered by letter in an effort to reflect the sequence of decisions; we are just trying to orient clinicians
rather than provide strict sequences.
3. Basic Mechanisms Involved in DIs between Atypical Antipsychotics and Anti-Infective
Agents
The various mechanisms involved in DIs can be categorized as either pharmacokinetic (PK) or
pharmacodynamic (PD).
3.1. PK DIs
PK DIs consist of modifications in the absorption, distribution, metabolism, or excretion of a
drug and/or its metabolite(s) after the addition of another drug. These DIs are associated with a
change in plasma concentration of either the drug or its metabolite(s) and are easily verified by
therapeutic drug monitoring (TDM).
PK DIs between atypical antipsychotics and anti-infective agents are largely mediated by drugmetabolizing enzymes, in particular, the hepatic cytochrome P450 (CYP) system and, to a lesser extent,
the uridine diphosphate glucuronosyltransferase (UGT) system, and by drug transporters in the gut,
liver, kidney, and brain such as the P-glycoprotein (P-gp).
The main clinically significant PK DIs between atypical antipsychotics and anti-infective agents
occur at a metabolic level and result from enzyme inhibition or induction. Available knowledge of
substrates, inhibitors, and inducers of the major drug-metabolizing enzymes has greatly improved
the possibility of predicting and eventually avoiding potential DIs [1]. In principle, concomitant
treatment with drugs metabolized by the same enzyme or coadministration of a drug with another
medication acting as an inhibitor or inducer involves a DI risk. A variety of drug-related (i.e., potency
and concentration/dose of the inhibitor/inducer, therapeutic index of the substrate, extent of
metabolism of the substrate through the affected enzyme, presence of active metabolites), patientrelated (i.e., age, genetic predisposition) and epidemiological factors (i.e., probability of concurrent
use) must be taken into account when evaluating the potential occurrence, magnitude and clinical
relevance of a metabolic DI [1].
PK parameters of atypical antipsychotics have been described in prior articles [3,4]. In summary,
CYP1A2 is the main metabolic pathway for clozapine and olanzapine; CYP3A4 is the main pathway
for cariprazine, lurasidone, and quetiapine; CYP2D6 and secondarily CYP3A4 metabolize
aripiprazole, brexpiprazole, iloperidone and risperidone; renal elimination is the main way to clear
amisulpride and paliperidone; aldehyde oxidase and secondarily CYP3A4 metabolize ziprasidone;
and CYP1A2 and UGTs are the main pathways for asenapine. Most atypical antipsychotics appear to
be neither inhibitors nor inducers of the major drug-metabolizing enzymes and only asenapine may
have weak CYP2D6 inhibitory properties. Therefore, these agents are not expected to give rise to PK
DIs with anti-infective agents unless unusual circumstances of saturation are present in which any
drug can behave as a competitive inhibitor. On the other hand, many anti-infective drugs may cause
metabolically-based DIs because they act as inhibitors or inducers of various drug-metabolizing
systems. In this respect, macrolides, fluoroquinolones, isoniazid, azole antimycotics, and
antiretrovirals act as strong inhibitors of CYP isoforms including CYP3A4 and CYP1A2 and may
therefore impair the elimination of atypical antipsychotics metabolized via these isoforms [10–14].
Conversely, the antitubercular drug rifampin induces the activity of CYP1A2, CYP2C9, CYP2C19,
and CYP3A4, as well as UGTs, thereby decreasing the plasma concentrations of a number of newer
antipsychotics [15].
PK DIs between atypical antipsychotics and anti-infective agents may also involve drug
transporters, in particular P-gp, a multidrug efflux transporter highly expressed in the small intestine,
brain, liver, and kidney that acts as a natural defense mechanism against several drugs by limiting
their absorption from the gut and penetration into the brain and promoting their elimination in the
bile and urine. Among anti-infective drugs, a number of azole antimycotics and antivirals inhibit
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various drug transporters including P-gp, while rifampin is known to induce the activity of P-gp.
There is some evidence suggesting that the atypical antipsychotics risperidone and paliperidone are
substrates of P-gp [16,17]. In theory, inhibition of P-gp by certain anti-infective drugs may increase
plasma and brain concentrations of these antipsychotics.
3.2. PD DIs
PD DIs occur when concomitantly administered medications share the same target sites of
actions (i.e., receptor) producing additive, synergistic or antagonistic effects that can enhance or
weaken the pharmacological action of either drug without any change in the plasma concentration.
While the mechanisms responsible for the therapeutic effect obviously differ between newer
antipsychotics and anti-infective drugs, concomitant administration of compounds of these two
classes may be associated with ADRs explained by a PD DI.
As a class, antipsychotic medications have the potential to prolong the corrected QT interval
(QTc), possibly leading to life-threatening ventricular arrhythmias including Torsades de Pointes
(TdP). However, atypical antipsychotics vary markedly in their effects on QTc with ziprasidone and
iloperidone associated with the most QTc prolongation and lurasidone, aripiprazole, brexpiprazole,
and cariprazine appear to have the least association with QTc prolongation [18,19]. Medications
belonging to various antimicrobial classes, including macrolides, fluoroquinolones, azole
antimycotics, antiretrovirals, and antimalarials, have been associated with QTc prolongation [20].
Combined use of atypical antipsychotics with anti-infective agents known to prolong the QTc interval
may result in additive effects on QTc interval prolongation, potentially leading to cardiac ADRs
including TdP and/or sudden death.
Atypical antipsychotics may cause or worsen metabolic abnormalities such as weight gain,
hyperglycemia, and hyperlipidemia, specifically the metabolic syndrome, which has been linked to
an increased cardiovascular risk [21]. Available evidence indicates that the risk of metabolic
disturbances is greatest with clozapine and olanzapine, moderate with risperidone and quetiapine,
and least with aripiprazole, ziprasidone, lurasidone, brexpiprazole, and cariprazine [22]. Among
anti-infective drugs, some antivirals, namely protease inhibitors, have classically been associated
with the development of metabolic changes [23,24]. Potentiation of metabolic effects may occur when
these medications are used concomitantly. Moreover, the human immunodeficiency virus (HIV)
infection may be also a contributor to metabolic syndrome [25].
Various classes of anti-infective agents can complicate the treatment of patients with prior
psychiatric disorders because they have the potential to cause neuropsychiatric ADRs including
psychotic symptoms [26,27]. The occurrence of psychotic symptoms induced by anti-infective agents
can decrease the benefits of antipsychotic agents.
Rarely some antibiotics have been associated with seizures [28]. Although it is not a wellunderstood topic, penicillins, cephalosporins, imipenem, and fluoroquinolones may have GABA
antagonist properties [28]. All atypical antipsychotics, but clozapine foremost and secondly
olanzapine and quetiapine can decrease the seizure threshold [29]. Although this potential PD DI has
not been studied, we cannot rule out that in rare patients the combinations of these antibiotics and
these atypical antipsychotics might contribute to seizures.
4. DIs between Atypical Antipsychotics and Anti-Infective Agents
4.1. Antibiotics
Antibiotics are among the most commonly prescribed drugs and many have properties that
predispose them to clinically significant DIs. Antibiotics are categorized into different classes based
on their mechanism of action, chemical structure, or spectrum of activity. In this section, only classes
of antibiotic agents with documented DIs with atypical antipsychotics will be considered in detail.
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4.1.1. Macrolides
Macrolide antibiotics, namely erythromycin, clarithromycin, and troleandomycin, are potent
inhibitors of CYP3A4 and, to a lesser extent, CYP1A2, and may therefore interfere with the
elimination of a number of atypical antipsychotics predominantly metabolized by these enzymes [10].
Controversial findings have been reported concerning the DIs between erythromycin and
clozapine. Two case reports have indicated that concomitant treatment with erythromycin resulted
in an elevation of plasma levels of clozapine, along with toxic effects such as somnolence,
disorientation, dizziness, nausea, and seizures [30,31]. Severe infections release cytokines and inhibit
CYPs, including CYP1A2, having the potential to cause a clozapine intoxication; these two case
reports did not consider that possibility [32]. A subsequent randomized crossover study in 12 healthy
male subjects documented that the PKs of clozapine, administered as a single dose of 12.5 mg, were
not significantly modified during coadministration with erythromycin, 1500 mg/day, suggesting a
limited involvement of CYP3A4 in the metabolism of clozapine in humans [33]. This study can be
criticized because, due to the short duration of the erythromycin phase, steady state was not reached
in this study, and doses of clozapine used were lower than those typically used in clinical practice.
On the other hand, other studies with potent CYP3A4 inhibitors [34] suggest no relevant effects on
clozapine levels. In summary, erythromycin is not likely to cause clozapine intoxication but any
severe infection that may be treated with erythromycin is likely to cause a clozapine intoxication.
A clinically significant PK DI may occur between macrolide antibiotics and quetiapine, a secondgeneration antipsychotic mainly metabolized via CYP3A4. In a PK investigation in Chinese patients
with schizophrenia, 19 subjects received multiple doses of quetiapine (400 mg/day) with or without
co-administered erythromycin (1500 mg/day) [35]. Concomitant administration with erythromycin
was associated with a significant increase in quetiapine maximal plasma concentration (Cmax), area
under concentration–time curve (AUC), and terminal-phase elimination half-life time (t1/2) by 68, 129,
and 92%, respectively, while quetiapine clearance decreased by 52%. These results were explained
by inhibition of CYP3A4-mediated metabolism of quetiapine by erythromycin. The potential clinical
relevance of this DI is highlighted by the case of a 32-year-old man with schizoaffective disorder and
metabolic syndrome who experienced a significant increase in quetiapine plasma concentration
following administration of clarithromycin, another macrolide antibiotic and strong CYP3A4
inhibitor. The patient, hospitalized for acute psychotic symptoms, was started with 50 mg/day of
quetiapine with a gradual increase in dosage to 700 mg/day over 10 days. Psychotic symptoms
disappeared within 3 weeks. On day 28, the patient developed a lower respiratory infection and was
treated with oral sultamicillin 750 mg and clarithromycin 500 mg along with his evening dose of
quetiapine 400 mg. The following morning, 750 mg sultamicillin, 500 mg clarithromycin, and 300 mg
quetiapine were given. Within two hours the patient became somnolent, and plasma quetiapine
levels were 827 ng/mL (normal range, 70 to 170 ng/mL). The patient developed severely impaired
consciousness and respiratory depression. Quetiapine overdose was suspected and treatment was
discontinued. Plasma levels were continually measured over the course of 1 week until complete
recovery was achieved [36].
Macrolide antibiotics may prolong the QTc interval [37]. Akathisia, a common antipsychotic
ADR, has occasionally been associated with erythromycin and clarithromycin in patients not taking
any antipsychotic [38]. Definitive cases of akathisia have been associated when macrolide agents are
added to atypical antipsychotics [39].
4.1.2. Fluoroquinolones
Ciprofloxacin, a broad-spectrum fluoroquinolone antimicrobial, is a strong CYP1A2 and a
moderate CYP3A4 inhibitor [11] with the potential to inhibit antipsychotics predominantly
metabolized by CYP1A2 (clozapine, olanzapine and asenapine).
In a 72-year-old man, the addition of ciprofloxacin treatment (1000 mg/day) on a
clozapinemaintenance regimen with a low dose (18.75 mg/day) caused a significant increase in
plasma clozapine concentration and suggested an inhibitory effect of ciprofloxacin on CYP1A2 [40].
A formal PK study further investigated this possible DI [41]. In this randomized, double-blind, cross-
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over study involving 7 schizophrenic inpatients stabilized on clozapine (dose ranging from 150 to
400 mg/day), concomitant administration of ciprofloxacin, 500 mg/day for 7 days, increased mean
serum concentrations of clozapine and norclozapine by 29% and 31%, respectively [41]. Interestingly,
these two publications involved low doses of either clozapine or ciprofloxacin. On the other hand, a
case description by Gex-Fabry et al. revealed the potential for a serious PK interaction, with clozapine
levels increasing by a factor of 3.4 from 354 to 1218 ng/mL after the addition of ciprofloxacin 1500
mg/day [42]. This potential DI with ciprofloxacin was formally acknowledged by the FDA in 2005
and reflected in a change in product labeling for clozapine in December 2005. Subsequent case reports
[43–47] documented that the PK DI between these two medications could lead to potentially fatal
clozapine intoxications.
The possibility of a PK DI between ciprofloxacin and olanzapine mediated by CYP1A2 inhibition
was suggested by a case report describing a patient on stable treatment with olanzapine whose serum
concentrations were almost doubled after initiation of ciprofloxacin with a dose of 500 mg/day [48].
The potential DI between ciprofloxacin and asenapine, a substrate of CYP1A2 and UGT1A4, was
not documented by TDM but suggested by an ADR of sudden-onset dystonia in a patient taking
asenapine soon after administration of 1000 mg/day of ciprofloxacin [49].
Two other fluoroquinolones, enoxacin, and norfloxacin, are also clinically relevant inhibitors of
CYP1A2 [50] but there is no documentation in the literature of a DI with atypical antipsychotics. On
the other hand, levofloxacin is not believed to be a CYP1A2 inhibitor [51] and did not influence
clozapine levels in a patient with pneumonia [52].
Fluoroquinolones have been associated with QTc interval prolongation [53]. Letsas et al. [54]
reported the case of an elderly patient receiving olanzapine who developed a marked QTc interval
prolongation after intravenous administration of ciprofloxacin.
4.1.3. Tetracyclines
Minocycline, a tetracycline antibiotic, has been reported to have beneficial effects on symptoms
of schizophrenia when administered as an add-on to antipsychotic therapy [55]. In a study in
clozapine-treated schizophrenic patients with persistent symptoms, 52 subjects were randomized to
receive minocycline, at a dose of 200 mg/day, or placebo for 10 weeks [56]. Coadministration with
minocycline was associated with a statistically significant increase (p = 0.033) in clozapine plasma
levels as compared to placebo, while no differences in plasma levels of norclozapine were found
between the two groups. As minocycline has been found to increase the exposure to theophylline, a
substrate for CYP1A2, it was hypothesized that inhibition of CYP1A2 may explain the increase in
plasma clozapine concentrations. The article’s research section did not provide data on the effect size
of the inhibition but it appears not to be clinically relevant since the discussion stated, “the average
increase in clozapine plasma level for the minocycline-treated group was 101.4 ng/mL, approximately
a 21% increase from baseline.”
4.1.4. Trimethoprim
Trimethoprim is part of the combined antibiotic trimethoprim-sulfamethoxazole. Trimethoprim
is an inhibitor of some renal transporters called organic cation transporters (OCTs) and multidrug
and toxin extrusion transporters (MATEs) [57]. A DI study in 30 healthy males by the paliperidone
marketer found no effects on paliperidone clearance, suggesting that other renal transporters should
be involved in paliperidone clearance [58]. It has been estimated that in normal individuals
approximately 38% of paliperidone is excreted by a renal transporter that still needs to be identified
[59].
4.1.5. Ampicillin
Csik and Molnar [60] proposed that a case of symptoms of clozapine intoxication during sinusitis
was explained by ampicillin inhibition of clozapine metabolism. As ampicillin is not known to be a
CYP inhibitor [5], the case was reinterpreted by proposing that the clozapine intoxication was
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explained by the cytokines released during the sinusitis [32]. The lack of another report describing
other cases of DIs in PubMed between clozapine and any other antipsychotic suggests that in effect
ampicillin is not a CYP inhibitor. Ampicillin is very frequently used around the world including in
patients taking atypical antipsychotics.
A practical summary of managing DIs between antibiotics and atypical antipsychotics is
reported in Table 1.
Table 1. Practical summary of managing drug interactions (DIs) between antibiotics and atypical
antipsychotics based on the authors’ knowledge at the time of publication of this article.
Antibiotics

Macrolides:
Erythromycin,
clarithromycin, and
troleandomycin, are
potent inhibitors of
CYP3A4.

Atypical
Antipsychotics
Cariprazine,
lurasidone, and
quetiapine mainly
metabolized by CYP3A4.
Aripiprazole,
brexpiprazole,
iloperidone, and
risperidone partly
metabolized by CYP3A4.

Outcome

Actions 1

Major ↑ level after adding
these macrolides [35,36].

Use another antibiotic when possible; the
inhibition is massive and severe ADRs have been
described with quetiapine.

↑ level after adding these
macrolides.
↓ level after D/C these
macrolides.

A. Use another antibiotic when possible.
B. No other option: use antipsychotic TDM.
C. No other option and no access to TDM: consider
antipsychotic dose correction factor of 0.50 during
the treatment (based on the effects of CYP34
inhibitors on these antipsychotics).

High-risk QTc
prolongation:
amisulpride,
iloperidone,
ziprasidone

Macrolides:
↑ QTc by inhibiting the
heart potassium channels.

Others have
intermediate risk.

A. Use another antibiotic or antipsychotic when
possible.
B. Never use without monitoring QTc.

Additive inhibition of the
heart potassium channels.
Greater effects with
greater dose or more
accurately described with
greater serum levels.
Remember some
macrolides can increase
levels of iloperidone and
risperidone [37].

Lowest risk QTc
prolongation:
lurasidone,
aripiprazole,
brexpiprazole and
cariprazine.

Fluoroquinolones:
Ciprofloxacin is a potent
inhibitor of CYP1A2 and
moderate CYP3A4.

Fluoroquinolones:
Enoxacin and norfloxacin
are relevant inhibitors of
CYP1A2.
Fluoroquinolones:
Levofloxacin is believed
NOT to be an inhibitor of
CYP1A2.

Fluoroquinolones:
↑ QTc by inhibiting the
heart potassium channels.

Clozapine and
olanzapine are mainly
metabolized by CYP1A2.
Asenapine is partly
metabolized by CYP1A2.
Clozapine and
olanzapine are mainly
metabolized by CYP1A2.
Asenapine is partly
metabolized by CYP1A2
Clozapine and
olanzapine are mainly
metabolized by CYP1A2.
Asenapine is partly
metabolized by CYP1A2.
High-risk QTc
prolongation:
amisulpride,
iloperidone,
ziprasidone.
Other have
intermediate risk.

A. Consider using another antibiotic when
possible.
B. Monitor QTc.
C. Torsades de Pointes is very rare, but the
additive risk factors are family history of sudden
death; personal history of syncope, arrhythmias or
heart conditions; hypokalemia, hypomagnesemia,
and co-prescription of other medications that ↑
QTc. Cases are more frequent in females aged > 65
years.
D. In the USA, consider the legal risk. Consider the
package insert warnings when combining them.

A. Monitor QTc.

↑ level after adding
ciprofloxacin.
↓ level after D/C
ciprofloxacin [41–48].
↑ level after adding
ciprofloxacin.
↓ level after D/C
ciprofloxacin [49].

A. Use another antibiotic when possible.
B. If no other choice, use dose correction factor for
clozapine (or olanzapine) of 0.33 and use TDM.
C. Consider monitoring QTc.
A. Use another antibiotic when possible.
B. If no other choice, consider decreasing dose and
use TDM when available.
C. Consider monitoring QTc.

↑ level after adding
antibiotics.
↓ level after D/C
antibiotics.

No data. Follow ciprofloxacin recommendation.

No changes in
antipsychotic levels are
expected [52].

A. Very limited data. Be careful and monitor
patient.
B. In clozapine patients use TDM when available.

Additive inhibition of the
heart potassium channels.
Greater effects with
greater dose or more
accurately described with
greater serum levels.

A. Use another antibiotic or antipsychotic when
possible.
B. Never use without monitoring QTc.
A. Consider using another antibiotic when
possible.
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Remember some
fluoroquinolones can
increase levels of clozapine,
olanzapine, and asenapine
[53,54].

Lowest risk QTc
prolongation:
lurasidone,
aripiprazole,
brexpiprazole and
cariprazine.
Tetracyclines:
Minocycline is a possible
mild CYP1A2 inhibitor.

Clozapine is mainly
metabolized by CYP1A2.

B. Monitor QTc.
C. Torsades de Pointes is very rare, but the
additive risk factors are family history of sudden
death; personal history of syncope, arrhythmias or
heart conditions; hypokalemia, hypomagnesemia,
and co-prescription of other medications that ↑
QTc. Cases are more frequent in females aged > 65
years.
D. In the USA, consider the legal risk. Consider the
package insert warnings when combining them.

A. Monitor QTc.

Mild ↑ level after adding
minocycline.
Mild ↓ level after D/C
minocycline [56].

A. Limited available data suggest that inhibitory
effects are not clinically relevant.
B. Consider TDM.

ADR: adverse drug reaction; D/C: discontinuing; DI: drug interaction; QTc: corrected QT interval; TDM:
therapeutic drug monitoring; ↑: increased; ↓: decreased. Italics are used in the text to reflect pharmacokinetic or
pharmacodynamic mechanisms. 1 A correction factor is used to modify dosing to account for DI. For example, a
correction factor of 0.5 indicates that the substrate dose should be halved. The recommendations are based on
the limited information available.

4.2. Antitubercular Agents
Rifampin, isoniazid, pyrazinamide, and ethambutol are first-line antitubercular medications
which are FDA-approved and indicated for the treatment of mycobacterium tuberculosis. Rifampin
and isoniazid are the only antituberculars with DI data with atypical antipsychotics.
4.2.1. Rifampin
The antitubercular agent rifampin is a potent inducer of both the hepatic and intestinal CYPs,
including CYP1A2 and CYP3A4, and the P-gp transport system [15]. Thus, it is expected to induce
the metabolism of most atypical antipsychotics which are cleared via CYP isoforms and/or are P-gp
substrates. Generally, full induction is reached in about 1 week after starting rifampin treatment and
the induction dissipates in roughly 2 weeks after discontinuing rifampin [61,62]. The induction is
near maximal at a dose of 300 mg/day [61].
Three case reports have documented the possibility of a PK DI between rifampin and clozapine [63–
65]. The first case reported a 33-year-old male schizophrenia patient stabilized on clozapine therapy (400
mg/day) who developed tuberculosis and was treated with rifampin 600 mg/day [63]. Within 2–3 weeks,
his clozapine plasma concentrations decreased approximately six-fold resulting in an exacerbation of
psychotic symptoms. A second case described a loss of clozapine efficacy caused by rifampin in a 30-yearold man with schizophrenia [64]. Clozapine therapy for 3 months at 300 mg/day controlled symptoms
with some dose-related ADRs (sedation, and hypersalivation). Following diagnosis of tuberculosis,
treatment with oral rifampin, 600 mg daily as monotherapy, was started. Two weeks later, the patient no
longer complained of sedation and hypersalivation, but his psychotic symptoms worsened. At the end of
the month, his psychopathology was as severe as when clozapine was first initiated. The dose of clozapine
was increased to 550 mg daily with only mild improvement. Following discontinuation of rifampin after
6 months of therapy, psychotic symptoms improved significantly, while sedation and hypersalivation
reappeared within 1 week. Though clozapine concentrations were not reported, fluctuations in
symptomatology and ADR were probably explained by an inducing effect of rifampin on clozapine
metabolism. In the third case, a 30-year-old female with paranoid schizophrenia had been relatively stable
for many years on 100 mg/day of clozapine [65]. Following the introduction of rifampin in a dose of 600
md/day, she experienced an acute and severe psychotic relapse. Her clozapine and norclozapine plasma
concentrations were subtherapeutic (less than 50 ng/mL). After discontinuation of rifampin, the clozapine
dose was slowly titrated up to 650 mg/day (clozapine levels 400 ng/mL) and over 2–3 months clinical
symptomatology gradually improved.
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Two formal PK investigations [66,67] evaluated the effect of rifampin on risperidone (metabolized
by CYP2D6 and, to a lesser extent, by CYP3A4). In an open, randomized two-phase crossover study
involving 10 Thai male volunteers, subjects received oral risperidone 4 mg alone or oral rifampin 600 mg
daily for 5 days followed by oral risperidone 4 mg [66]. Concomitant administration of risperidone with
rifampin was associated with a significant decrease in the AUC (by 72%; p < 0.01), Cmax (by 50%; p < 0.05)
when compared with risperidone alone. A randomized, open-label, 2-way crossover study in 10 healthy
Korean volunteers found similar results [67]. The pharmacokinetics of a single 1 mg oral dose of
risperidone were investigated before and after 7 days with 600 mg rifampin or placebo. Rifampin
significantly decreased the AUC of risperidone, 9-hydroxyrisperidone, and the active moiety by 51%, 43%,
and 45%, respectively. These two studies provided in vivo evidence of the involvement of CYP3A4 in the
metabolism of risperidone but P-gp induction may also be a contributing factor.
Lurasidone is mainly metabolized by CYP3A4. In 20 healthy volunteers, the coadministration of a
single dose of lurasidone 40 mg with rifampin 600 mg/day at steady-state (for 8 days) resulted in a
decrease in lurasidone Cmax and AUC by approximately 85% and 82%, respectively, relative to lurasidone
administration alone [68].
4.2.2. Isoniazid
Isoniazid is a clinically relevant CYP1A2 inhibitor [13]. A case report described a 65-year-old
Caucasian male with a clozapine concentration-dose (C/D) ratio of 0.99 ng/mL per mg/day (and a
total C/D ratio of 1.95). The addition of isoniazid increased the C/D (and total 1.95) ratios between
1.73–2.41 (2.73–3.82) while its discontinuation led to normalization of the clozapine C/D ratio to 1.20
(2.30) [69]. According to an in vitro study, isoniazid may be a clinically relevant CYP3A4 inhibitor
[70], thus it may be a clinically relevant inhibitor of antipsychotics metabolized by CYP3A4.
A practical summary of managing DIs between antibiotics and atypical antipsychotics is
included in Table 2.
Table 2. Practical summary of managing DIs between antitubercular agents and atypical
antipsychotics based on the authors’ knowledge at the time of publication of this article.
Antitubercular Agents

Rifampin is an inducer of
multiple metabolic enzymes
and transporters.

Atypical Antipsychotics
Clozapine and olanzapine are
mainly metabolized by CYP1A2.
Aripiprazole, brexpiprazole,
iloperidone and risperidone are
partly metabolized by CYP3A4.
Cariprazine, lurasidone and
quetiapine are mainly metabolized by
CYP3A4.
During induction, paliperidone may
be mainly metabolized by CYP3A4.Pgp induction may also decrease
paliperidone effects.

Isoniazid is an inhibitor of
CYP1A2 and CYP3A4.

Clozapine and olanzapine are
mainly metabolized by CYP1A2.
Aripiprazole, brexpiprazole,
iloperidone, and risperidone are
partly metabolized by CYP3A4.
Cariprazine, lurasidone, and
quetiapine are mainly metabolized by
CYP3A4.
Asenapine is partly metabolized by
CYP1A2.

Outcome

↓ level 1 week
after adding
rifampin.
↑ level 2 weeks
after D/C
rifampin [63–
68].

↑ level after
adding
isoniazid.
↓ level after D/C
isoniazid [69].

Actions 1
A. Consider another antitubercular agent or atypical antipsychotic when
possible. Amisulpride and ziprasidone may be the least influenced by
induction.
B. No other option: use antipsychotic TDM.
C. No other option and no access to TDM we can only provide
recommendations based on the effects of potent inducers on these
antipsychotics by using dose correction factors of: 2 (for clozapine,
olanzapine, aripiprazole, brexpiprazole, iloperidone, or risperidone) and
3 (for paliperidone).
D. We cannot provide any dose correction factor for asenapine and
access to its TDM is limited.
E. We do not recommend combining rifampin with cariprazine,
lurasidone, or quetiapine even with access to TDM since, based on the
effects of potent inducers such as carbamazepine on these
antipsychotics, the needed correction factor may be 5 or even higher.
A. Consider another antituberculosis agent or atypical antipsychotic
when possible. Amisulpride, paliperidone and ziprasidone may be the
least influenced by inhibition.
B. No other option: use antipsychotic TDM.
C. No other option and no access to TDM: we can only provide
recommendations based on the effects of potent inhibitors on these
antipsychotics by using dose correction factors of: 0.5 (for clozapine,
olanzapine, aripiprazole, brexpiprazole, iloperidone, and risperidone).
D. We cannot provide any dose correction factor for asenapine and
access to its TDM is limited.
E. We do not recommend combining isoniazid with cariprazine,
lurasidone or quetiapine unless clinician has expertise in their TDM.

D/C: discontinuing; DI: drug interaction; TDM: therapeutic drug monitoring; ↑: increased; ↓:
decreased. Italics are used in the text to reflect pharmacokinetic or pharmacodynamic mechanisms. 1 A
correction factor is used to modify dosing to account for DI. For example, a correction factor of 0.5
indicates that the substrate dose should be halved. The recommendations are based on the limited
information available.
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4.3. Antifungals
Azole antimycotics have the potential to cause clinically significant DIs when co-administered
with atypical antipsychotics.
Azole Antimycotics
Azole antifungal drugs (namely, fluconazole, itraconazole, ketoconazole, posaconazole, and
voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal
infections. They are CYP and P-gp inhibitors [12]. Their inhibitory potential varies greatly:
itraconazole, ketoconazole, and posaconazole are more potent inhibitors of CYP3A4 than are
fluconazole or voriconazole [12]. In addition to CYP3A4, fluconazole and voriconazole are also strong
noncompetitive or mixed-type inhibitors of CYP2C9 and CYP2C19 [71].
Ketoconazole has been tested in clinical studies during the development of various atypical
antipsychotics that are metabolized by CYP3A4 [9].
In 27 patients treated with quetiapine, concomitant administration of ketoconazole, 400 mg/day,
resulted in a 4-fold increase in a mean quetiapine peak plasma concentration [72]. In 12 healthy
volunteers receiving 25 mg quetiapine before and after 4 days of treatment with ketoconazole 200 mg
daily, concomitant use of ketoconazole increased the mean Cmax and AUC of quetiapine by 235% and
522%, respectively, and decreased its clearance by 84% [73]. In a study in 10 healthy subjects,
coadministration of a single dose of lurasidone 10 mg with ketoconazole 400 mg/day at steady state
(for 5 days) caused a 9.3-fold increase in lurasidone AUC, and a 6.8-fold increase in Cmax, as compared
to lurasidone alone [68]. These findings are consistent with inhibition of CYP3A4 by ketoconazole.
In an open-label, randomized, crossover study conducted in 10 healthy male volunteers, the PKs
of a single oral dose of 2 mg of risperidone were investigated alone or in combination with
ketoconazole, 200 mg/day for 3 days [74]. Ketoconazole pretreatment resulted in a significant increase
in the AUC of risperidone by 67% (p < 0.001) and a decrease in its clearance by 35% (p < 0.05).
In a placebo-controlled, randomized, crossover study in 14 healthy subjects, concomitant
administration of ziprasidone, given as a single dose of 40 mg, with ketoconazole, 400 mg/day for 2
weeks, was associated with a modest increase in ziprasidone exposure [75]. Mean Cmax and AUC of
ziprasidone increased significantly (p < 0.05) by 34% and by 33%, respectively, as compared with
placebo.
Two studies in patients with schizophrenia have investigated the possibility of a PK DI between
azole antimycotics and clozapine. A double-blind, placebo-controlled, randomized study, performed
in 7 schizophrenia patients, documented no significant changes in PK parameters of clozapine during
coadministration with itraconazole, 200 mg/day for one week [76]. In a study involving 5
schizophrenia patients, a single clozapine dose of 50 mg was given before and after 7 days of coadministration with ketoconazole 400 mg/day [77]. PK parameters of clozapine and its two major
metabolites, norclozapine and clozapine-N-oxide, did not change significantly during ketoconazole
co-administration. The findings of these two studies indicate that CYP3A4 inhibition may not be
clinically significant compared to CYP1A2.
Jung et al. [78] investigated the effect of a treatment with itraconazole, 200 mg/day for a week,
on plasma concentrations of risperidone and its active metabolite in 19 schizophrenia patients
stabilized on risperidone therapy (2–8 mg/day) in relation to CYP2D6 genotype. Itraconazole
increased the mean steady-state plasma concentrations of risperidone active fraction by 71% and 73%
in CYP2D6 extensive and poor metabolizers, respectively. As the ratio of risperidone/9-OHrisperidone, an index of CYP2D6 activity was not affected by itraconazole administration, this DI was
attributed to inhibition of CYP3A4, an isoform playing a secondary role in the 9-hydroxylation of
risperidone. In another PK investigation, coadministration of itraconazole, 100 mg/day for 7 days, to
24 healthy male volunteers increased the Cmax, the AUC, and the half-life of aripiprazole and its main
metabolite by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively [79].
The PK of single doses of lurasidone (20 mg) were investigated in 11 healthy normal-weight
volunteers and 13 otherwise healthy obese subjects before and during the administration of
posaconazole, 300 mg/day [80]. During posaconazole coadministration, the AUC of lurasidone

Pharmaceuticals 2020, 13, 439

11 of 25

increased by a factor of 6.2 in normal volunteers and by a factor of 4.9 in obese subjects, reflecting the
strong inhibitory effect of posaconazole on CYP3A4 activity.
Azole antifungal agents are known to cause QT interval prolongation [81]. Therefore,
concomitant use of newer antipsychotics with azole antimycotics may result in overlapping cardiac
toxicity.
Ketoconazole was studied under very well-controlled randomized conditions but eliminating
patients with cardiac risk. In the study funded by the ziprasidone marketer, 400 mg/day of
ketoconazole was added to 2 atypical antipsychotics [82]. In 31 patients taking 160 mg/day
ziprasidone led to a mean QTc increase of 15.9 ms from baseline with almost no change after adding
ketoconazole. In 27 patients, taking 750 mg/day of quetiapine led to a mean QTc increase of 5.7 ms
from baseline with some increase after adding ketoconazole (value in figure was estimated to be
around 8 ms). In the study funded by the iloperidone marketer, 400 mg/day of ketoconazole was
added to 3 atypical antipsychotics [83]. Adding ketoconazole in 35 patients taking 160 mg/day
ziprasidone led to a mean QTc increase of 15.9 ms from baseline and 6 ms from only ziprasidone.
Adding ketoconazole, in 35 patients taking 750 mg/day of quetiapine led to a mean QTc increase of
2.6 ms from baseline. Adding ketoconazole in 39 patients taking 16 mg/day of iloperidone and 20
mg/day of paroxetine the QTc increased as an average 15.7 ms from baseline. Adding ketoconazole
in 39 patients taking 24 mg/day of iloperidone and 20 mg/day of paroxetine the QTc increased as an
average 19.3 ms compared to baseline. Adding ketoconazole in 35 patients taking 48 mg/day of
iloperidone and 20 mg/day of paroxetine the QTc increased as an average 19.5 ms compared to
baseline. In summary, in this ketoconazole dose and in these selected patients in those two
antipsychotic trials, the effects of ketoconazole on QTc appear to be mainly explained by a PK DI and
there were limited effects of the increase of QTc due to PD cardiac effects of ketoconazole.
All azoles had the risk of further QTc prolongation when prescribed with any atypical
antipsychotic and this may be potentiated by their PK effects.
A practical summary of managing DIs between antibiotics and atypical antipsychotics is
reported in Table 3.
Table 3. Practical summary of managing DIs between antifungals and atypical antipsychotics based
on the authors’ knowledge at the time of publication of this article.
Antifungals

Itraconazole, ketoconazole, and
posaconazole are potent
inhibitors of CYP3A4 and they
prolong QTc by inhibiting the
heart potassium channels.

Fluconazole and voriconazole
appear to be mild to moderate
CYP3A4 inhibitors but they
prolong QTc by inhibiting the
heart potassium channels.

Atypical Antipsychotics
Cariprazine, lurasidone, and
quetiapine are mainly metabolized by
CYP3A4.
Aripiprazole, brexpiprazole,
iloperidone, and risperidone are partly
metabolized by CYP3A4.
Clozapine and olanzapine are mainly
metabolized by CYP1A2.
Asenapine is partly metabolized by
CYP1A2.
Inhibition of metabolism of amisulpride
may be minimal and of ziprasidone
may be small but they cause greater
prolongation of QTc interval by
inhibiting the heart potassium channels.
High-risk QTc prolongation:
amisulpride, iloperidone, ziprasidone.

Others have intermediate risk.
More risk for those depending on
CYP3A4 for their metabolism
(quetiapine and risperidone).

Lowest risk QTc prolongation:
lurasidone, aripiprazole, brexpiprazole
and cariprazine.

Outcome

Actions

↑ level of CYP3A4
antipsychotics after
adding azole.
↓ level of CYP3A4
antipsychotics after
D/C azole.
Additive effects on
QTc prolongation
[72–83].

A. Do not use combinations of these azoles with atypical
antipsychotics metabolized by CYP3A4 (cariprazine,
lurasidone, quetiapine, aripiprazole, brexpiprazole,
iloperidone, and risperidone).
B. Do not use combinations of these azoles with atypical
antipsychotics with high risk of QTc prolongation
(amisulpride, iloperidone, and ziprasidone).
C. Adding these azoles to clozapine, olanzapine, and
paliperidone may have minimal inhibitory effects on their
metabolism but additive effects on QTc prolongation
should be expected. Monitoring QTc is recommended.

Additive effects on
QTc prolongation
[81].

A. Use another antifungal or antipsychotic when possible.
B. Never use without monitoring QTc.
A. Consider using another antifungal when possible.
B. Monitor QTc.
B. Monitor TDM for quetiapine and risperidone.
D. Torsades de Pointes is very rare, but the additive risk
factors are family history of sudden death; personal history
of syncope, arrhythmias, or heart conditions; hypokalemia,
hypomagnesemia, and co-prescription of other
medications that ↑ QTc. Cases are more frequent in females
aged > 65 years.
E. In the USA, consider the legal risk. Consider the
package insert warnings when combining them.
A. Monitor QTc.

D/C: Discontinuing; DI: drug interaction; QTc: corrected QT interval; TDM: therapeutic drug
monitoring; ↑: increased; ↓: decreased. Italics are used in the text to reflect pharmacokinetic or
pharmacodynamic mechanisms.
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4.4. Antivirals
Pharmacological treatment of viral infections has evolved significantly over the last decades
with a large number of new agents actually available. The prevalence of some severe viral infections
including HIV, hepatitis B, and hepatitis C in patients with severe psychiatric disorders is much
higher than in the general population [84]. Many people with psychiatric problems engage in
behaviors that increase their risk of infection with blood-borne viruses, including intravenous drug
use resulting from co-occurring substance misuse problems and unprotected sex with multiple
partners. Atypical antipsychotic drugs are frequently co-prescribed with antiviral agents used to treat
these severe infections, possibly resulting in clinically significant DIs.
4.4.1. Antiretrovirals
Psychotic symptoms are relatively common in patients with HIV, so that antipsychotics and
antiretroviral agents may be prescribed in combination. Antiretroviral drugs include various classes
such as nucleoside/nucleotide reverse transcriptase inhibitors (i.e., zidovudine, lamivudine, abacavir,
emtricitabine, tenofovir), non-nucleoside reverse transcriptase inhibitors (i.e., delavirdine, efavirenz,
nevirapine, etravirine, rilpivirine), and protease inhibitors (i.e., atazanavir, darunavir, fosamprenavir,
indinavir, lopinavir, nelfinavir, ritonavir, saquinavir). Many antiretroviral drugs are prone to PK DIs
because they are substrates as well as inhibitors of inducers of several CYP isoforms [14].
All members of the protease inhibitor class are particularly strong inhibitors of CYP3A4, with
ritonavir being the most potent. Indeed, this drug is commonly used at low doses in HIV treatment
(100–200 mg/d) not for its antiviral activity but rather to take advantage of its inhibition of CYP3A4,
which “boosts” the plasma concentrations of co-administered protease inhibitors and thereby allows
for once-daily dosing. Ritonavir has a greater potential for DI than other protease inhibitors because
it also inhibits CYP2D6. Moreover, ritonavir and indinavir are potent inducers of CYP1A2 and UGT.
In addition, protease inhibitors are also substrates and inhibitors of P-gp. Non-nucleoside reverse
transcriptase inhibitors also have a variety of effects on CYP isoforms. With regard to this, efavirenz,
nevirapine, and etravirine are inducers of CYP3A4, whereas efavirenz and etravirine are inhibitors
of CYP2C9 and CYP2C19. Rilpivirine does not substantially affect CYP3A4 and is therefore less
commonly involved in DI than other members of this class.
Modern combination antiretroviral therapy consists of at least three antiretroviral agents which
may obviously enhance the risk of DIs. Clinically relevant DIs between antiretrovirals and
psychotropic drugs including atypical antipsychotics have recently been reviewed [85,86].
A clinically significant DI may occur when risperidone is co-administered with protease
inhibitors. A number of case reports have documented the occurrence of ADRs such as
extrapyramidal symptoms [87], reversible coma [88], neuroleptic malignant syndrome [89], and lateonset angioedema [90] in patients receiving risperidone associated with ritonavir/indinavir,
presumably due to inhibition of risperidone metabolism. As ritonavir is known to be a strong
inhibitor of both CYP3A4 and CYP2D6 and indinavir is known to inhibit CYP3A4, concomitant
administration of indinavir or ritonavir would be expected to alter metabolism of risperidone.
Quetiapine is also a CYP3A4 substrate and concomitant treatment with ritonavir and other
protease inhibitors can increase its serum concentrations. Pollack et al. [91] described two patients
who developed weight gain and hyperglycemia (first case) and marked sedation and mental
confusion (second case) after the addition of quetiapine to an antiretroviral regimen containing
ritonavir and atazanavir. As with ritonavir, atazanavir is also a moderate inhibitor of CYP3A4. While
there are no specific recommendations in the quetiapine labeling for dose adjustments with protease
inhibitors, if concurrent use is necessary, the quetiapine dose should be reduced to one-sixth of the
original dose [86]. Hantson et al. [92] described a case of quetiapine overdose (total 8000 mg ingested)
in a 47-year-old female patient concomitantly taking lamivudine (300 mg/day), ritonavir (100
mg/day), atazanavir (350 mg/day), and tenofovir (245 mg/day) for an HIV infection. Major clinical
complications consisted of a deep coma and sustained hypotension. The PK data documented a
quetiapine half-life of 62 h, which is 10 times the half-life reported in quetiapine’s package insert, and
still nearly 3 times the 22-h terminal elimination half-life calculated for a patient following quetiapine
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overdose (3000 mg) in the absence of CYP3A4 inhibitors [93]. Such a prolonged terminal half-life of
quetiapine observed in this case was explained either by CYP3A4 saturation in overdose conditions
or by CYP3A4 inhibition by concomitant medications.
Aripiprazole is metabolized by CYP2D6 and CYP3A4. Two case reports are available describing
ADRs with the co-administration of aripiprazole and antiretroviral therapy. The first case describes
an antiretroviral regimen including darunavir boosted with ritonavir, and concomitant aripiprazole,
duloxetine, and buspirone [94], which led to multiple hospital admissions as well as supratherapeutic
aripiprazole serum concentrations attributed to a DI between aripiprazole and the antiretroviral
therapy. Conversely, in a case of a patient receiving antiretroviral containing a ritonavir-boosted
protease inhibitor, the patient experienced lower-than-expected aripiprazole serum levels with
clinical worsening after being converted from oral to depot aripiprazole using the manufacturer’s
recommended conversion [95]. The patient was ultimately stabilized on double the recommended
monthly dose.
Lurasidone is primarily metabolized via CYP3A4. Ritonavir and other protease inhibitors, such
as nelfinavir and saquinavir, are specifically mentioned in the lurasidone package insert as examples
of strong CYP3A4 inhibitors which are contraindicated with lurasidone. Atazanavir is a moderate
CYP3A4 inhibitor and lurasidone dose should be halved when given with atazanavir. Despite these
theoretical interactions, there is limited information on these expected DI. Naccarato et al. reported
the case of a 63-year-old HIV patient, concomitantly treated with lurasidone and atazanavir, who
developed extrapyramidal symptoms associated with elevated serum concentrations of lurasidone.
Extrapyramidal adverse effects disappeared following atazanavir discontinuation [96]. One major
confounder in this case was the possible contribution of concomitant risperidone to parkinsonian
symptoms.
Olanzapine is metabolized via CYP1A2 and UGT1A4. Ritonavir can induce CYP1A2 and UGTs,
thus raising concern about the possibility of subtherapeutic olanzapine levels with coadministration.
In an open-label crossover study in 14 healthy volunteers, the PKs of a single 10 mg oral dose of
olanzapine were investigated before and during coadministration of ritonavir, 600–1000 mg/day [97].
Administration of ritonavir resulted in a significant 53% decrease in olanzapine AUC (p < 0.001), in a
significant decrease in olanzapine half-life from 32 h to 16 h (p < 0.0001), and in a significant increase
in olanzapine clearance (p < 0.001). The ritonavir doses in this particular study are much higher than
in modern practice. Another open-label crossover study, conducted in 20 healthy subjects,
investigated the DI between olanzapine and ritonavir, employing a 200 mg/day dose of ritonavir,
which more accurately reflects modern-day practice [98]. Increasing the olanzapine dose by 50%
(from 10 to 15 mg/day) when co-administered with fosamprenavir 700 mg/ritonavir 200 mg/day (for
16 days) compensated for the induction (of CYP1A2- and UGT-mediated) olanzapine metabolism
and resulted in olanzapine exposure that was comparable to when olanzapine 10 mg was
administered alone. Based on the results of these studies, a 50% increase in olanzapine dose is
warranted when given concomitantly with ritonavir containing antiretroviral regimens.
Being a potent inducer of CYP3A4, efavirenz may decrease plasma concentrations of some
newer antipsychotics and reduce their efficacy.
In addition to potential PK DIs, concomitant use of newer antipsychotics with antiretrovirals
may be associated with ADR potentiation by PD mechanisms.
Both newer antipsychotics and antiretrovirals, in particular protease inhibitors, are associated
with metabolic abnormalities such as weight gain, hyperglycemia, and hyperlipidemia. Concerning
protease inhibitors, these ADRs were reported more often with older agents (i.e., ritonavir) than with
newer compounds (i.e., darunavir and atazanavir) [23,99,100]. Despite the high rate of HIV and
psychiatric comorbidity and the known metabolic effects of atypical antipsychotics and
antiretrovirals, the metabolic consequences of this combined treatment have received virtually no
coverage in the literature. With regard to this, a retrospective study including 2229 patients with HIV
and severe mental illness, examined the effect of concurrent use of atypical antipsychotics and
antiretrovirals on metabolic parameters associated with increased cardiovascular risk [101]. Patients
treated with both antiretrovirals and atypical antipsychotics were more likely to have higher blood
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pressure, higher diabetes prevalence, and higher serum triglycerides as compared to those only
taking an atypical antipsychotic. General recommendations for the management of overlapping
metabolic toxicities in patients receiving both antiretrovirals and newer antipsychotics include
evaluating underlying risk, monitoring laboratory parameters, encouraging lifestyle modifications,
switching agents if possible or adding additional therapy, communicating among providers, and
providing patient education [99].
A potential PD DI that may occur when combining atypical antipsychotics with a number of
antiretrovirals is additive QTc prolongation. Among antiretrovirals, the protease inhibitors lopinavir,
nelfinavir, ritonavir and saquinavir, and the non-nucleoside reverse transcriptase inhibitors efavirenz
and rilpivirine have been associated with QTc prolongation [20,102].
Clozapine has been documented to be effective in HIV patients with refractory schizophrenia.
However, its use is associated with the risk of hematologic toxicity resulting in leukopenia,
neutropenia, and potentially fatal agranulocytosis. Of the antiretrovirals, zidovudine is known to
have myelosuppressive effects [103]. Their combined use should be avoided. While psychosis is a
recognized manifestation of HIV, psychotic symptoms may be secondary to certain antiretrovirals
including efavirenz, zidovudine, nevirapine, and ganciclovir [104–106] and they may theoretically
reduce the benefits of concomitantly administered atypical antipsychotics.
4.4.2. Direct-Acting Antivirals
For several years, pegylated interferon-α and ribavirin have been the only available treatment
for chronic hepatitis C virus (HCV). Since the development of novel direct-acting antivirals these
agents are no longer used. There are three main classes of direct-acting antivirals, depending on the
nonstructural protein that target for inhibition: NS3/4A protease inhibitors (boceprevir, telaprevir,
simeprevir, grazoprevir, paritaprevir, glecaprevir, voxilaprevir), NS5A inhibitors (ledipasvir,
daclatasvir, ombitasvir, elbasvir, velpatasvir, pibrentasvir) and NS5B polymerase inhibitors
(sofosbuvir, dasabuvir). These agents are usually given in combinations of two to up to five drugs,
thereby enhancing the possibility of DIs.
Each of the available direct-acting antivirals has its own metabolism and presents a different
potential for DIs [107]. Moreover, these agents can potentially interact with a variety of psychotropic
agents via CYPs and P-gp. Smolders et al. reviewed DIs between the first approved direct-acting
antivirals and other concomitant medications including antipsychotics [108]. A recent review by
Roncero et al. has specifically assessed the DI potential of each of the currently available direct-acting
antivirals with psychotropic drugs [109]. Though these agents are frequently co-prescribed with
atypical antipsychotics, no study has investigated the possibility of DIs between agents of these two
classes. Based on theoretical knowledge of the PK properties of drugs [108,109], boceprevir,
simeprevir, the combination regimen paritaprevir/ombitasvir/ritonavir/dasabuvir and the
combination elbasvir/grazoprevir are the most likely direct-acting antivirals to cause DIs with some
antipsychotics via the inhibition of CYP3A4 and/or P-gp (paliperidone). On the other hand, no
clinically significant DIs are expected when atypical antipsychotics are co-administered with the most
commonly
used
combination
regimens
including
velpatasvir/sofosbuvir
and
glecaprevir/pibrentasvir.
A practical summary of managing DIs between antibiotics and atypical antipsychotics is
included in Table 4.
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Table 4. Practical summary of managing DI between antivirals and atypical antipsychotics based on
the authors’ knowledge at the time of publication of this article.
Antivirals

Atypical Antipsychotics
Cariprazine, lurasidone, and
quetiapine are mainly
metabolized by CYP3A4.
Aripiprazole, brexpiprazole,
iloperidone, and risperidone
are partly metabolized by
CYP3A4.

Antiretrovirals:
Ritonavir is a potent inhibitor of CYP3A4, CYP2D6, and P-gp and an
inducer of CYP12 and UGT. It prolongs QTc by inhibiting the heart
potassium channels.

Clozapine and olanzapine
are mainly metabolized by
CYP1A2.

Asenapine is metabolized by
UGT and CYP1A2.

Clozapine and olanzapine
are mainly metabolized by
CYP1A2.
Antiretrovirals:
Indinavir is an inducer of CYP12 and UGT. It prolongs QTc by
inhibiting the heart potassium channels.
Asenapine is metabolized by
UGT and CYP1A2.

Cariprazine, lurasidone, and
quetiapine are mainly
metabolized by CYP3A4.
Aripiprazole, brexpiprazole,
and risperidone are partly
metabolized by CYP3A4.
Antiretrovirals:
Efavirenz, nevirapine, and etravirine are CYP3A4 inducers. They
prolong QTc by inhibiting the heart potassium channels.
High-risk QTc prolongation:
amisulpride, iloperidone,
ziprasidone.

Antiretrovirals:
Nelfinavir and saquinavir are strong inhibitors of CYP3A4
Atazanavir is a moderate inhibitor of CYP3A4. They prolong QTc by
inhibiting the heart potassium channels.

Cariprazine, lurasidone, and
quetiapine are mainly
metabolized by CYP3A4.
Aripiprazole, brexpiprazole,
and risperidone are partly
metabolized by CYP3A4.

High-risk QTc prolongation:
amisulpride, iloperidone,
ziprasidone.

Antiretrovirals:
Zidovudine has risk of bone marrow suppression

Direct-acting antivirals: Boceprevir, simeprevir, the combination
paritaprevir/ombitasvir/ritonavir/dasabuvir, and the combination of
elbasvir/grazoprevir are CYP3A4 and/or P-gp inhibitors.

Clozapine can cause
agranulocytosis possibly due
to immunological mechanisms.
Cariprazine, lurasidone and
quetiapine are mainly
metabolized by CYP3A4.
Aripiprazole, brexpiprazole,
iloperidone, and risperidone
are partly metabolized by
CYP3A4.

Outcome
↑ level of these
antipsychotics after
adding ritonavir.
↓ level of these
antipsychotics after
D/C ritonavir.
Additive effects on
QTc prolongation
[20,87–96,102].
↓ level after adding
ritonavir.
↑ level after D/C
ritonavir.
Additive effects on
QTc prolongation
[20,97,98,102].
Likely ↓ level after
adding ritonavir.
Likely ↑ level after
D/C ritonavir.
Additive effects on
QTc prolongation
[20,102].
↓ level after adding
indinavir.
↑ level after D/C
indinavir.
Additive effects on
QTc prolongation.
Likely ↓ level after
adding indinavir.
Likely ↑ level after
D/C indinavir.
Additive effects on
QTc prolongation.
↓ level after adding
antivirals.
↑ level after D/C
antivirals.
Additive effects on
QTc prolongation
[20,102].
Additive effects on
QTc prolongation.
↓ level of
iloperidone after
adding antivirals.
↑ level of
iloperidone after
D/C antivirals
[20,102].
↑ level after adding
antivirals.
↓ level after D/C
antivirals.
Additive effects on
QTc prolongation
[20,102].
Additive effects on
QTc prolongation
[20,102].
↑ level of
iloperidone after
adding antiviral.
↓ level of
iloperidone after
D/C antiviral.

Actions
A. Do not combine ritonavir
with these
antipsychotics. Serious ADRs
have been described.
B. If you decide to take the risk
of combining them use
antipsychotic TDM and QTc
monitoring.
A. Consider alternatives.
B. Use TDM for better dosing
of clozapine and
olanzapine.
C. Monitor QTc.

A. Do not combine ritonavir
with asenapine. There is no
data to provide
recommendations.

A. Consider alternatives.
B. Use TDM for better dosing
clozapine and
olanzapine.
C. Monitor QTc.
A. Do not combine indinavir
with asenapine. There is no
data to provide
recommendations.

A. Consider alternatives.
B. Use TDM for better dosing
these antipsychotics.
C. Monitor QTc.

A. Do not combine.

A. Consider alternatives.
B. Use TDM for better dosing
of these antipsychotics.
C. Monitor QTc.

A. Do not combine.

Additive effects
cannot be ruled out.

A. Do not combine.

↑ level after adding
antivirals.
↓ level after D/C
antivirals [108,109].

A. Consider alternatives.
B. Use TDM for better dosing
these antipsychotics.

ADR: adverse drug reaction; D/C: discontinuing; DI: drug interaction; QTc: corrected QT interval;
TDM: therapeutic drug monitoring; ↑: increased; ↓: decreased. Italics are used in the text to reflect
pharmacokinetic or pharmacodynamic mechanisms.
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4.5. Other Anti-Infective Agents
Use of the antimalarials chloroquine and hydroxychloroquine and the antiparasitic pentamidine
can lead to a prolongation of the QT interval, possibly increasing the risk of TdP and sudden cardiac
death [20]. These agents should not be combined with atypical antipsychotics with higher risk for
QTc prolongation, such as amisulpride, iloperidone and ziprasidone, and iloperidone.
The possibility of PK DIs caused by these two agents has not been systematically studied but
hydroxychloroquine can be a clinically relevant CYP2D6 inhibitor [110] and can increase the serum
concentrations of aripiprazole, brexpiprazole, iloperidone, and risperidone. On the other hand,
chloroquine does not appear to act as a CYP2D6 inhibitor [111].
A practical summary of managing DIs between antibiotics and atypical antipsychotics is
reported in Table 5.
Table 5. Practical summary of managing DIs between other anti-infective agents and atypical
antipsychotics based on the authors’ knowledge at the time of publication of this article.
Other Anti-Infective Agents

Hydroxychloroquine is a
CYP2D6 inhibitor. It prolongs
QTc by inhibiting the heart
potassium channels.

Chloroquine prolongs QTc by
inhibiting the heart potassium
channels.
It may be more prone to cause
psychiatric symptoms than
hydroxychloroquine.

Atypical Antipsychotics

Outcome

Actions 1
A. Consider
alternatives.
B. Use TDM for better
dosing these
antipsychotics.
C. In absence of TDM
considering a dose
correction of 0.5 for
these antipsychotics.
D. Monitor QTc.

Aripiprazole,
brexpiprazole, and
risperidone are partly
metabolized by CYP2D6.

↑ level of these
antipsychotics after adding
hydroxychloroquine.
↓ level of these
antipsychotics after D/C
hydroxychloroquine.
Additive effects on QTc
prolongation [20].

High risk QTc
prolongation: amisulpride,
iloperidone, ziprasidone by
inhibiting the heart potassium
channels.

Additive effects on QTc
prolongation [20].
↑ level of iloperidone after
adding
hydroxychloroquine.
↓ level of iloperidone after
D/C hydroxychloroquine.

A. Do not combine.

High risk QTc
prolongation: amisulpride,
iloperidone, ziprasidone by
inhibiting the heart potassium
channels.

Additive effects on QTc
prolongation [20].

A. Do not combine.

D/C: Discontinuing; DI: drug interaction; QTc: corrected QT interval; TDM: therapeutic drug
monitoring; ↑: increased; ↓: decreased. Italics are used in the text to reflect pharmacokinetic or
pharmacodynamic mechanisms. 1 A correction factor is used to modify dosing to account for DI. For
example, a correction factor of 0.5 indicates that the substrate dose should be halved. The
recommendations are based on the limited information available.

5. Contribution of Infections
Using information from Section 4, Tables 1–5 provides a summary of the DI of different classes
of anti-infective agents. These tables ignore the fact that patients taking anti-infective agents and
atypical antipsychotics frequently have active infections that may also have effects at the PK and PD
mechanisms influenced by anti-infective agents and/or atypical antipsychotics. Although it is
impossible to review all of these possible PK and PD effects caused by infections, Table 6 tries to
provide some practical guidelines when clinicians face acute new problematic symptoms in patients
taking anti-infective agents and atypical antipsychotics. They include QTc prolongation, psychosis,
seizures, and symptoms compatible with an antipsychotic intoxication. Of those, we only discuss the
two most lethal ADRs: QTc prolongation and pneumonia with clozapine intoxication.
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Table 6. New symptoms during infection when patients are co-prescribed anti-infective agents and
atypical antipsychotics.
Situation

Anti-Infective Agents

Atypical Antipsychotics

During infection: ↑ QTc
Consider direct effects of infection in heart.

Risk of ↑ QTc: macrolides,
fluoroquinolones, azole
antimycotics, some antivirals,
and antimalarials by inhibiting
the heart potassium channels.

All can cause ↑ QTc but
highest risk for amisulpride,
iloperidone, and
ziprasidone by inhibiting the
heart potassium channels.

Some anti-infective agents
have been associated as
causal agents of psychosis.

All APs have antipsychotic
efficacy by inhibiting D2
receptors (antagonists or
partial agonists) at basal
ganglia and/or cortex.
Occasionally psychotic
exacerbations have been
suggested by aripiprazole
case reports by being a D2
partial agonist at basal ganglia
and/or cortex.

Seizures during infection. Consider brain
effects of infection.

Penicillins, cephalosporins,
imipenem, and
fluoroquinolones may have
GABA antagonist properties.

By ↓ seizure threshold:
Highest risk: clozapine.
2nd riskiest: olanzapine and
quetiapine.
3rd riskiest: rest of atypical
antipsychotics.

During infection symptoms compatible
with clozapine intoxication (including
sedation, hypersalivation, myoclonus, or
seizure).

Never use ciprofloxacin,
enoxacin, and norfloxacin
which are relevant inhibitors of
CYP1A2.

Presence of fever or CRP
elevations are signs that
cytokine release may inhibit
CYP1A2.

During infection: exacerbation of psychosis
in patients with underlying illness or
appearance in patients who never presented
psychosis.
Consider brain effects of infection.

During infection symptoms compatible
with olanzapine intoxication (including
sedation).

Never use ciprofloxacin,
enoxacin, and norfloxacin
which are relevant inhibitors of
CYP1A2.

During infection symptoms compatible
with antipsychotic intoxication and patient
on antipsychotic dependent on CYP3A4.
Cariprazine, lurasidone and quetiapine are
mainly metabolized by CYP3A4. Aripiprazole,
brexpiprazole, iloperidone and risperidone
are partly metabolized by CYP3A4.

Never use erythromycin,
clarithromycin, and
troleandomycin which are
relevant inhibitors of CYP3A4.

Presence of fever or CRP
elevations are signs that
cytokine release may inhibit
CYP1A2.
Although not well-studied,
elevations of serum
olanzapine concentrations
may be lower than in
clozapine.
Presence of fever or CRP
elevations are signs that
cytokine release may inhibit
CYP3A4.
Although not well-studied,
elevations of serum
concentrations of these
antipsychotics may be
lower than in clozapine.

Actions
A. Avoid using antipsychotics with highest
risk.
B. Be vigilant even when only one risky drug is
present. Consider the need for QTc
monitoring.
C. Torsades de Pointes is very rare, but the
additive risk factors are family history of
sudden death; personal history of syncope,
arrhythmias, or heart conditions; hypokalemia,
hypomagnesemia, and co-prescription of other
medications that ↑ QTc. Cases are more
frequent in females aged > 65 years.
D. In the USA, consider the legal risk. Consider
the package insert warnings when combining
them.
A. Extremely complex situation. Consider all
possible causal factors.
B. Involve other medical specialties in
diagnosis.
C. Psychiatrist needs to carefully review
PK/PD DIs of all drugs, one by one, and timing
of the psychosis; help other medical specialties
to think clearly.
D. If possible, change only one variable at a
time.
A. Extremely complex situation.
Consider all possible causal factors.
B. Involve neurologist in diagnosis.
C. Psychiatrist needs to carefully review
PK/PD DIs of all drugs, one by one, and timing
of the seizure; help other medical specialties to
think clearly.
D. If possible, change only one variable at a
time.
A. Tell patient and/or family to call
psychiatrist when fever or sign of infection
occurs.
B. If fever and/or CRP elevation develop, cut
clozapine dose in half unless clozapine TDM is
immediately available.
C. Once clozapine intoxication occurs, cut
clozapine to one-third of the dose or stop
completely.
D. If possible, monitor clozapine TDM.
E. Do not go back to prior clozapine dose until
CRP is normal.
A. If fever and/or CRP elevation develop and
signs of olanzapine intoxication are present,
consider cutting olanzapine dose in half unless
olanzapine TDM is immediately available.
B. If possible, monitor olanzapine TDM.
C. Do not go back to prior olanzapine dose
until CRP is normal.

A. If fever and/or CRP elevation develop and
signs of antipsychotic intoxication are present,
consider decreasing the dose unless TDM is
immediately available.
B. If possible, monitor TDM.
C. Do not go back to prior antipsychotic dose
until CRP is normal.

CRP: c-reactive protein; D/C: Discontinuing; DI: drug interaction; PK: pharmacokinetic; PD:
pharmacodynamic; QTc: corrected QT interval; TDM: therapeutic drug monitoring; ↑: increased; ↓:
decreased. Italics are used in the text to reflect pharmacokinetic or pharmacodynamic mechanisms.

Extreme QTc prolongation > 450 ms is usually considered a risk marker for TdP which is
potentially lethal. Sudden deaths associated with TdP have an incidence in the range of 1/1000–
1/10,000 patients; therefore, most clinicians using antipsychotics may never have seen a case of TdP
but, unfortunately, they continue to occur [112]. In the experience of the authors, the problem is that
some psychiatrists ignore all or most DIs in their patients and this may not be lethal until the “wrong”
patient is treated by them [113]. So using high doses of antipsychotics or combining them with other
QTc-prolonging drugs can be non-lethal in many patients, but then cause a sudden death when
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multiple risk factors are accumulated in a specific patient. Moreover, a very high dose of an
antipsychotic can be safe in a prior admission, but then cause a sudden death presumably explained
by TdP when other factors are added in the same patient [112]. The recent COVID-19 epidemic in
which many patients with serious comorbidity are treated with risky drugs helps to explain the
difficulty of extrapolating from QTc prolongation to Torsades de Pointes even in situations of highrisk during infections. In this regard, a recent study included 87 Italian patients treated with 3 antiinfective agents (lopinavir/ritonavir, hydroxychloroquine, and azithromycin) with potential for QTc
prolongation and provided a definition of QTc prolongation (an absolute QTc interval ≥ 500 ms or an
increase in QTc intervals of ≥60 ms or greater compared with baseline). QTc prolongation was
frequent and present in 20 patients [114]. In these 20 patients, 10 had a discontinuation of at least one
of these 3 drugs and 3 died. Only 1 case of Torsades de Pointes was identified among 17 surviving
patients. Clinicians expecting evidence-based medicine (EBM) approaches in this area must
understand that there will never be a well-controlled prospective study that can unequivocally
demonstrate that a specific drug combination is safe in a specific patient. These studies cannot
accurately replicate the specific characteristics of a specific patient. DIs cannot be understood in the
framework of EBM focused on average patients, but rather in the framework of personalized
medicine in which each patient is different [115].
Severe infections are usually manifested with signs of generalized inflammation including fever
and serum c-reactive protein (CRP) elevations secondary to the cytokines released. The literature is
accumulating information that the cytokines can inhibit several CYPs [116]. There is definitive
information that inflammation can increase serum clozapine concentrations [32,117]. More limited is
the information on olanzapine, which is also metabolized by CYP1A2 [118], and in the antipsychotics
dependent on CYP3A4 [119,120]. This peculiar DI, caused by inflammation-released cytokines, may
be relevant for clozapine use. Clozapine probably has the narrowest therapeutic index of all atypical
antipsychotics [121]. This may explain why in a study of the ADRs reported to the FDA, clozapine
ranked as the third most lethal drug with 3277 deaths [122]. In a review of clozapine ADRs reported
to an international database by all national drug agencies, pneumonia was associated with 2077
deaths versus 1149 sudden deaths or 550 deaths associated with agranulocytosis [123]. In this
database, pneumonia was more closely associated to clozapine than other antipsychotics [124] but,
according to a study in a national registry database, the variables associated with treatmentrefractoriness may be more important contributors to pneumonia than clozapine [125]. The lethality
of pneumonia in clozapine patients is probably due to a combination of pneumonia and the
associated clozapine intoxication [126]. Decreasing the clozapine dosage during infections with
systemic inflammation may be a good idea [52]. Cases of clozapine intoxication are starting to be
described during pneumonia associated with the COVID-19 virus [127].
6. Conclusions
After a comprehensive search of the literature, Section 4 describes the limited information
published on DIs between atypical antipsychotics and anti-infective agents. The reader should
remember that the lack of published studies or case reports does not preclude the occurrence of DIs
in their patients. Thus, based on our prior articles of DIs of atypical antipsychotics [3,4,8,29,121] and
our current understanding of PK and PD mechanisms, we have developed practical
recommendations for clinicians summarized in Table 1 for antibiotic DIs, Table 2 for antitubercular
DIs, Table 3 for antifungal DIs, Table 4 for antiviral DIs, and Table 5 for other anti-infective DIs. We
have never in prior articles used a table such as Table 6 interpreting DIs in the complexity of clinical
practice. DIs between atypical antipsychotics and anti-infective agents do not happen in a laboratory
but in a live patient who also has an infection that may influence the PK and PD mechanisms of all
administered drugs. These tables reflect the currently available literature and our current knowledge
of the field and will need to be updated as new DI information becomes available allowing us to
provide better practical recommendations. We remind the reader to look for future updates of this
article and others focused on atypical antipsychotic DIs. Hopefully, the reader will agree with us that
this article is much better and more practical than our first attempt to write about DIs in atypical
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antipsychotics 13 years ago [8]. Anyway, with all of its limitations, this is the only published review
focused on the DIs between atypical antipsychotics and anti-infective agents. Finally, we encourage
researchers to publish new studies on DIs in atypical antipsychotics and anti-infective agents and
that, in the absence of these studies, case reports published by clinicians may be the only way to move
the field forward.
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